Intravesical Enfortumab Vedotin in Non-Muscle Invasive Bladder Cancer

What is the Purpose of this Study?

If you choose to join this study, you will:
- Get a dose of the study drug once a week for 6 weeks, then monthly for nine months
- Have hysical xxams, blood draws, and give urine samples
- Have MRI or CT scans
- Have a cystoscopy
- Have a bladder biopsy
What is the Condition Being Studied?
Non-Muscle Invasive Bladder Cancer (NMIBC)

Who Can Participate in this Study?

Adults ages 18+ who:

- Are diagnosed with NMIBC

- Do not respond to Bacillus Calmette-Guerin (BCG) therapy

- Are ineligible for or do not want to have a radical cystectomy

- Have a working bladder and are able to "hold it" for at least one hour after the study drug is given

- Are not pregnant

For more information about who can join this study, please contact the study team at

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if an investigational drug called enfortumab vedotinin (the study drug) is a safe and effective treatment for NMIBC.

Study Details

Full Title
A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)
Principal Investigator

Protocol Number

View on